| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
31,350,000 |
| Market
Cap: |
16.03(M) |
| Last
Volume: |
15,038 |
Avg
Vol: |
14,996 |
| 52
Week Range: |
$0.2127 - $0.648 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Catalyst Biosciences is a research and clinical development biopharmaceutical company. Co.'s complement portfolio consists of the development candidates CB 4332 and CB 2782-PEG. CB 4332 is a wholly owned, improved albumin-fused Complement Factor I (CFI) molecule intended for prophylactic subcutaneous or intravitreal administration in individuals with an imbalance in complement homeostasis or a CFI deficiency. CB 2782-PEG is a potential component 3 degrader product candidate in preclinical development for the treatment of dry age-related macular degeneration. Co. has several engineered protease programs in discovery or early non-clinical development.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
9,750 |
| Total Buy Value |
$0 |
$0 |
$0 |
$4,584 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
60,000 |
60,000 |
60,000 |
60,000 |
| Total Sell Value |
$950,777 |
$950,777 |
$950,777 |
$950,777 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
3 |
3 |
3 |
3 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lawlor Augustine |
Director |
– • – |
2018-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,732 |
2,732 |
|
- |
|
| Desouza Errol B |
Director |
– • – |
2018-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
1,703 |
1,944 |
|
- |
|
| Hunt Andrea |
Director |
– • – |
2018-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
811 |
811 |
|
- |
|
| Levy Howard |
Chief Medical Officer |
• – – |
2018-11-26 |
4 |
OE |
$4.63 |
$690 |
D/D |
149 |
7,709 |
|
- |
|
| Levy Howard |
Chief Medical Officer |
• – – |
2018-11-16 |
4 |
AS |
$11.00 |
$1,903 |
D/D |
(173) |
7,560 |
|
- |
|
| Levy Howard |
Chief Medical Officer |
• – – |
2018-11-16 |
4 |
OE |
$4.63 |
$801 |
D/D |
173 |
7,733 |
|
- |
|
| Hill Stephen A |
Director |
– • – |
2018-09-06 |
4 |
D |
$10.07 |
$1,913 |
D/D |
(190) |
1,190 |
|
- |
|
| Levy Howard |
Chief Medical Officer |
• – – |
2018-05-03 |
4 |
OE |
$4.63 |
$35,003 |
D/D |
7,560 |
7,560 |
|
- |
|
| Usman Nassim |
President & CEO |
• • – |
2018-04-09 |
4 |
GA |
$0.00 |
$0 |
I/I |
88 |
4,144 |
|
- |
|
| Usman Nassim |
President & CEO |
• • – |
2018-04-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
88 |
0 |
|
- |
|
| Usman Nassim |
President & CEO |
• • – |
2018-04-04 |
4 |
OE |
$4.63 |
$407 |
D/D |
88 |
88 |
|
- |
|
| Payne Fletcher |
Chief Financial Officer |
• – – |
2018-03-26 |
4 |
OE |
$4.63 |
$273 |
D/D |
59 |
59 |
|
- |
|
| Deerfield Partners, Lp |
Possible Member of 10% Group |
– – • |
2018-03-08 |
4/A |
S |
$29.03 |
$271,631 |
I/I |
(9,317) |
305,965 |
|
- |
|
| Deerfield Special Situations Fund, L.p. |
Possible Member of 10% Group |
– – • |
2018-03-08 |
4 |
S |
$29.03 |
$271,631 |
I/I |
(9,317) |
1,113,222 |
|
- |
|
| Deerfield Partners, Lp |
Possible Member of 10% Group |
– – • |
2018-03-07 |
4/A |
S |
$30.00 |
$300,000 |
I/I |
(10,000) |
308,526 |
|
- |
|
| Deerfield Special Situations Fund, L.p. |
Possible Member of 10% Group |
– – • |
2018-03-07 |
4 |
S |
$30.00 |
$300,000 |
I/I |
(10,000) |
1,122,539 |
|
- |
|
| Deerfield Partners, Lp |
Possible Member of 10% Group |
– – • |
2018-03-06 |
4/A |
S |
$29.94 |
$1,619,414 |
I/I |
(52,461) |
311,274 |
|
- |
|
| Deerfield Special Situations Fund, L.p. |
Possible Member of 10% Group |
– – • |
2018-03-06 |
4 |
S |
$29.94 |
$1,619,414 |
I/I |
(52,461) |
1,132,539 |
|
- |
|
| Usman Nassim |
President & CEO |
• • – |
2015-12-17 |
4 |
B |
$2.00 |
$8,000 |
I/I |
4,000 |
78,375 |
2.58 |
- |
|
| Payne Fletcher |
Chief Financial Officer |
• – – |
2015-12-17 |
4 |
B |
$2.00 |
$20,000 |
I/I |
10,000 |
25,032 |
1.99 |
- |
|
| Hill Stephen A |
Director |
– • – |
2015-12-17 |
4 |
B |
$2.03 |
$10,150 |
D/D |
5,000 |
20,711 |
2.39 |
- |
|
| Hill Stephen A |
Director |
– • – |
2015-08-28 |
4 |
D |
$6.72 |
$81,621 |
D/D |
(12,146) |
15,711 |
|
- |
|
| Essex Woodlands Health Ventures Viii, L.p. |
10% Owner |
– – • |
2015-08-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,179,352 |
|
- |
|
| Selick Harold E |
Director |
– • – |
2015-08-20 |
4 |
A |
$0.00 |
$0 |
I/I |
382 |
16,614 |
|
- |
|
| Selick Harold E |
Director |
– • – |
2015-08-20 |
4 |
A |
$0.00 |
$0 |
D/D |
16,232 |
16,232 |
|
- |
|
141 Records found
|
|
Page 5 of 6 |
|
|
